76 related articles for article (PubMed ID: 15298367)
1. Plan-sponsor savings and member experience with point-of-service prescription step therapy.
Motheral BR; Henderson R; Cox ER
Am J Manag Care; 2004 Jul; 10(7 Pt 1):457-64. PubMed ID: 15298367
[TBL] [Abstract][Full Text] [Related]
2. Health plan member experience with point-of-service prescription step therapy.
Cox ER; Henderson R; Motheral BR
J Manag Care Pharm; 2004; 10(4):291-8. PubMed ID: 15298527
[TBL] [Abstract][Full Text] [Related]
3. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
4. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
Clark BE; Siracuse MV; Garis RI
Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
[TBL] [Abstract][Full Text] [Related]
5. Controlling prescription drug expenditures: a report of success.
Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
[TBL] [Abstract][Full Text] [Related]
6. Mitigation of medication mishaps via medication therapy management.
Pindolia VK; Stebelsky L; Romain TM; Luoma L; Nowak SN; Gillanders F
Ann Pharmacother; 2009 Apr; 43(4):611-20. PubMed ID: 19336646
[TBL] [Abstract][Full Text] [Related]
7. Policy versus practice: comparison of prescribing therapy and durable medical equipment in medical and educational settings.
Sneed RC; May WL; Stencel C
Pediatrics; 2004 Nov; 114(5):e612-25. PubMed ID: 15520092
[TBL] [Abstract][Full Text] [Related]
8. Impact of patient and plan design factors on switching to preferred statin therapy.
Cox ER; Kulkarni A; Henderson R
Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
[TBL] [Abstract][Full Text] [Related]
9. A 30-month evaluation of the effects on the cost and utilization of proton pump inhibitors from adding omeprazole OTC to drug benefit coverage in a state employee health plan.
West DS; Johnson JT; Hong SH
J Manag Care Pharm; 2006; 12(1):25-32. PubMed ID: 16420105
[TBL] [Abstract][Full Text] [Related]
10. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
[TBL] [Abstract][Full Text] [Related]
11. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit.
Rodin HA; Heaton AH; Wilson AR; Garrett NA; Plocher DW
Am J Manag Care; 2009 Dec; 15(12):881-8. PubMed ID: 20001169
[TBL] [Abstract][Full Text] [Related]
12. Comparison of mail-order with community pharmacy in plan sponsor cost and member cost in two large pharmacy benefit plans.
Johnsrud M; Lawson KA; Shepherd MD
J Manag Care Pharm; 2007 Mar; 13(2):122-34. PubMed ID: 17330973
[TBL] [Abstract][Full Text] [Related]
13. The effects of antihypertensive step-therapy protocols on pharmaceutical and medical utilization and expenditures.
Mark TL; Gibson TB; McGuigan KA
Am J Manag Care; 2009 Feb; 15(2):123-31. PubMed ID: 19284809
[TBL] [Abstract][Full Text] [Related]
14. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan.
Harris BN; West DS; Johnson J; Hong SH; Stowe CD
J Manag Care Pharm; 2004; 10(5):449-55. PubMed ID: 15369428
[TBL] [Abstract][Full Text] [Related]
15. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation.
Motheral BR; Henderson R
Am J Manag Care; 1999 Nov; 5(11):1383-94. PubMed ID: 10662412
[TBL] [Abstract][Full Text] [Related]
16. Effect of a therapeutic maximum allowable cost (MAC) program on the cost and utilization of proton pump inhibitors in an employer-sponsored drug plan in Canada.
Mabasa VH; Ma J
J Manag Care Pharm; 2006 Jun; 12(5):371-6. PubMed ID: 16792443
[TBL] [Abstract][Full Text] [Related]
17. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
[TBL] [Abstract][Full Text] [Related]
18. Impact of 2 employer-sponsored population health management programs on medical care cost and utilization.
Mattke S; Serxner SA; Zakowski SL; Jain AK; Gold DB
Am J Manag Care; 2009 Feb; 15(2):113-20. PubMed ID: 19284808
[TBL] [Abstract][Full Text] [Related]
19. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
20. Use and employer costs of a pharmacotherapy smoking-cessation treatment benefit.
Burns ME; Rosenberg MA; Fiore MC
Am J Prev Med; 2007 Feb; 32(2):139-42. PubMed ID: 17196785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
